Hypoactive Sexual Desire Disorder in Women: Physiology, Assessment, Diagnosis, and Treatment

Hypoactive sexual desire disorder (HSDD) is the most common form of female sexual dysfunction, yet it has historically lacked effective treatment options. This comprehensive clinical review by Pettigrew and Novick in the Journal of Midwifery and Women's Health examined the physiology, assessment, diagnosis, and treatment of HSDD.

The authors reviewed the pathophysiology underlying HSDD, current diagnostic criteria, and available treatment modalities. Their analysis provided clinicians with a practical framework for identifying and managing this condition, with particular attention to evidence-based pharmacological interventions.

The review validated bremelanotide (PT-141) as an effective treatment for HSDD in women, affirming its clinical utility based on trial evidence and post-marketing data. The peptide's unique mechanism through melanocortin receptor activation was highlighted as a distinguishing advantage.

For women's health practitioners, this review supports evidence-based prescribing of PT-141 for HSDD. By clearly outlining the assessment pathway and treatment evidence, the study empowers clinicians to confidently incorporate peptide therapy into their management of female sexual dysfunction.